RenovoRx RNXT
NASDAQ RNXT
$1.27 -0.05 (-3.39%)
As of: Aug 21, 2026 · 9:38 AM EDT

RenovoRx (RNXT) Operating Leases (2024 - 2026)

RenovoRx (RNXT) posted Operating Leases of $78000.0 for Q1 2026, down 63.21% sequentially from $212000.0 in Q4 2025, and down 58.06% YoY from $186000.0 in Q1 2025.

RenovoRx (RNXT) Operating Leases (2024 - 2026) Analysis & Trends

RenovoRx has reported Operating Leases for 3 years, with the latest figure at $78000.0 in Q1 2026.

  • Quarterly Operating Leases fell 58.06% year-over-year to $78000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78000.0 (down 58.06% YoY) and the FY2025 annual result came in at $212000.0, changed 0.0% from the prior year.
  • Operating Leases fell to $78000.0 in Q1 2026 per RNXT's latest filing, from $212000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $212000.0 in Q4 2024 and troughed at $78000.0 in Q1 2026.
  • A 3-year average of $163833.3 and a median of $173500.0 in 2025 frame the typical range for Operating Leases.
  • The sharpest annual moves came in 2025 and 2026: Operating Leases changed 0.0% in 2025, then tumbled 58.06% in 2026.
  • Over 3 years, Operating Leases stood at $212000.0 in 2024, then changed by 0.0% to $212000.0 in 2025, then plunged by 63.21% to $78000.0 in 2026.
  • According to Business Quant data, Operating Leases over the past three periods registered $78000.0, $212000.0, and $134000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.41 Bn 130.56 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.12 Bn 78.12 Bn 3.93 Bn
3 Argenx Se 64.41 Bn 59.23 Bn 1.37 Bn
4 Moderna 57.56 Bn 52.43 Bn 52.00 Mn
5 BeOne Medicines 42.06 Bn 36.96 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.95 Bn 27.65 Bn 992.69 Mn
7 BioNTech SE 27.48 Bn 9.09 Bn 668.28 Mn
8 Insmed 27.31 Bn 26.15 Bn 358.27 Mn
9 Royalty Pharma 27.04 Bn 26.20 Bn -
10 RenovoRx 60.29 Mn 60.29 Mn 766,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 390,000.00
Mar 31, 2026 78,000.00
Dec 31, 2025 212,000.00
Sep 30, 2025 134,000.00
Jun 30, 2025 161,000.00
Mar 31, 2025 186,000.00
Dec 31, 2024 212,000.00